The U.S. Supreme Court has declined to review a case involving Zimmer Biomet Holdings and the cessation of royalty payments related to knee replacement devices. Zimmer Biomet challenged a decision by the Seventh Circuit that ruled against the company for discontinuing royalty payments on these devices, which were developed using an orthopedic surgeon’s patented technologies. The contention arose when Zimmer Biomet ceased these payments following the expiration of the patents in question.
This refusal to hear the case effectively upholds the lower court’s decision. For more detailed information, the original article by Adam Lidgett can be found on Law360.